ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
124.305,57
-0,34%
S&P 500
5.304,72
0,70%
US Dollar vs BRL
5,1713
0,00%
Bitcoin
68.679,48
0,25%
Brent Oil
82,125
0,18%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Contravir Pharmaceuticals (MM) (CTRV)

  7. Contravir Pharmaceuticals (MM) (CTRV) Notícias

CTRV

Contravir Pharmaceuticals Inc (CTRV)

Contravir Pharmaceuticals (MM)
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CTRV
DataHoraFonteTítuloCódigoCompanhia
08/11/201908:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CTRVContravir Pharmaceuticals (MM)
21/10/201917:26Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:CTRVContravir Pharmaceuticals (MM)
14/08/201918:30Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CTRVContravir Pharmaceuticals (MM)
29/07/201917:15GlobeNewswire Inc.Hepion Pharmaceuticals Receives FDA Authorization to Proceed with IND Opening Study of CRV431 for NASHNASDAQ:CTRVContravir Pharmaceuticals (MM)
25/07/201917:17Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CTRVContravir Pharmaceuticals (MM)
22/07/201915:00GlobeNewswire Inc.ContraVir Pharmaceuticals Announces Name Change to Hepion Pharmaceuticals, Inc.; Trading Symbol Change to “HEPA”NASDAQ:CTRVContravir Pharmaceuticals (MM)
28/06/201909:43Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:CTRVContravir Pharmaceuticals (MM)
27/06/201909:00GlobeNewswire Inc.ContraVir Pharmaceuticals Submits IND Application for CRV431 for NASHNASDAQ:CTRVContravir Pharmaceuticals (MM)
20/06/201917:30GlobeNewswire Inc.ContraVir Pharmaceuticals Receives Positive FDA Response to CRV431 Pre-IND Package for NASHNASDAQ:CTRVContravir Pharmaceuticals (MM)
19/06/201918:26Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)NASDAQ:CTRVContravir Pharmaceuticals (MM)
18/06/201909:45GlobeNewswire Inc.ContraVir Pharmaceuticals, Inc. Announces Pricing of $15.6 Million Public OfferingNASDAQ:CTRVContravir Pharmaceuticals (MM)
18/06/201907:01Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:CTRVContravir Pharmaceuticals (MM)
17/06/201909:00GlobeNewswire Inc.Compelling Positive Results Reported from Human Liver Experiments with ContraVir Pharmaceuticals’ NASH Drug CandidateNASDAQ:CTRVContravir Pharmaceuticals (MM)
13/06/201917:37Edgar (US Regulatory)Withdrawal of a Registration Statement Withdrawal Request (rw Wd)NASDAQ:CTRVContravir Pharmaceuticals (MM)
13/06/201916:31Edgar (US Regulatory)Withdrawal of Registration Statement (rw)NASDAQ:CTRVContravir Pharmaceuticals (MM)
12/06/201911:57Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:CTRVContravir Pharmaceuticals (MM)
12/06/201907:03Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:CTRVContravir Pharmaceuticals (MM)
11/06/201909:30GlobeNewswire Inc.ContraVir Pharmaceuticals Announces Publication of CRV431 Data from Experimental Model of Hepatitis BNASDAQ:CTRVContravir Pharmaceuticals (MM)
06/06/201909:00GlobeNewswire Inc.ContraVir Pharmaceuticals Sets the Stage for CRV431 Development in NASH with Positive Results from Second Model of Liver Fibr...NASDAQ:CTRVContravir Pharmaceuticals (MM)
31/05/201909:00GlobeNewswire Inc.ContraVir Pharmaceuticals, Inc. Announces Reverse Stock SplitNASDAQ:CTRVContravir Pharmaceuticals (MM)
20/05/201915:46Edgar (US Regulatory)Securities Registration Statement (s-1)NASDAQ:CTRVContravir Pharmaceuticals (MM)
06/05/201909:00GlobeNewswire Inc.ContraVir Pharmaceuticals Receives Positive Nasdaq Listing DecisionNASDAQ:CTRVContravir Pharmaceuticals (MM)
29/04/201909:30GlobeNewswire Inc.ContraVir Pharmaceuticals to Present at the 2019 ThinkEquity ConferenceNASDAQ:CTRVContravir Pharmaceuticals (MM)
25/04/201910:02GlobeNewswire Inc.ContraVir Pharmaceuticals, Inc. Announces Pricing of $2.14 Million Public OfferingNASDAQ:CTRVContravir Pharmaceuticals (MM)
11/04/201909:00GlobeNewswire Inc.ContraVir Pharmaceuticals to Present CRV431 Phase 1 Data at the International Liver Congress™NASDAQ:CTRVContravir Pharmaceuticals (MM)
02/04/201918:07Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:CTRVContravir Pharmaceuticals (MM)
02/04/201910:37Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:CTRVContravir Pharmaceuticals (MM)
27/03/201916:45Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:CTRVContravir Pharmaceuticals (MM)
18/03/201918:07Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:CTRVContravir Pharmaceuticals (MM)
14/03/201908:02Edgar (US Regulatory)Annual Report (10-k)NASDAQ:CTRVContravir Pharmaceuticals (MM)
 Apresentando as notícias mais relevantes sobre:NASDAQ:CTRV

Seu Histórico Recente

NYSE
PERF
Perfect
BIT
IVS
IVS
EU
KORAF
Kempen Orange Fund Nv
ASX
WGO
Warrego Energy
EU
ALKLK
Kerlink
TSXV
HET.H
LSE
NICL
Nichols
BOV
VIVR11
VIVER ON
NASDAQ
MDIV
First Trust VI Multi Ass...
NYSE
EVT
Eaton Vance Tax Advantag...
NYSE
SBH
Sally Beauty
NASDAQ
VXUS
Vanguard Total Internati...
LSE
RTC
Rtc
TSX
URB
Urbana
LSE
0O7Q
Enerxy Ia
NYSE
TAV
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados